Acer Therapeutics Inc.

37 articles with Acer Therapeutics Inc.

• Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle DisordersTopline trial results expected in Q1 2021; targeting a pre-NDA meeting with FDA in Q2 2021

  12/22/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of its pivotal trial evaluating the bioequivalence (BE) of ACER-001 compared to BUPHENYL® (sodium phenylbutyrate)

• Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from SwedenAuthors report that celiprolol may have a protective effect in COL3A1-positive vEDS patients

  12/17/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the publication of additional long-term data from COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS) patients in the European Journal of Vascular and Endovascular Surgery (EJVES).

• Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/10/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2020, and provided an update on the Company’s recent corporate developments. “This quarter, we continued to make important progress in the advanceme

• Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital

  10/1/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at, and participate in, the BIO Investor Forum Digital

• Acer Therapeutics to Virtually Present at Upcoming Investor Conferences

  8/25/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September,

• Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

  8/13/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2020,

• Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study

  7/8/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), today announced data from a food effect study in healthy volunteers showing that administration of ACER-001 in a fasted state increased systemic exposure of phenylbutyrate (PBA), phenylacetate (PAA) and phenylacetylglutamine

• Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

  5/14/2020

  Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital

• Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health

  5/11/2020

  Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance

• Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital

  4/30/2020

  Acer Therapeutics Inc. announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

• Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

  3/18/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the Company’s recent corporate developments.

• Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New DrugsOffice of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™

  3/18/2020

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has denied Acer’s appeal of the Complete Response Letter (CRL) in relation to the New Drug Application (NDA) for EDSIVO™

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®

  2/24/2020

  Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data

• 

  Clinical Catch-Up: December 16-20

  12/23/2019

  Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.

• Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders

  12/16/2019

  Part A Successfully Completed and Optimal Formulation of ACER-001 Identified Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

• Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

  11/13/2019

  NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent corporate developments. “We have been very active as we continue to progress the development of

• 

  Clinical Catch-Up: October 28-Nov 1

  11/4/2019

  Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.

• Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle DisordersResults Expected in Q1 2020 with a Planned NDA Submission in Q1 2021

  10/28/2019

  Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part A in a pivotal trial evaluating bioavailability and bioequivalence of ACER-001 for the treatment of Urea Cycle Disorders (UCDs).

• FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019

  8/27/2019

  Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Acer Therapeutics Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Acer securities purchased between September 25, 2017 and June 24, 2019, inclusive.